Introduction and Objective: Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows significant cardiometabolic benefits in Western population. However, data from Indian ethnicity with distinct genetics and metabolic phenotype remain scarce. This study aimed to evaluate the efficacy of tirzepatide on cardiometabolic parameters in the Indian patients with obesity. Methods: This prospective observational study included 91 adults with obesity from a tertiary care centre in India. Comprehensive metabolic profile including anthropometric indices (weight, BMI), glycemic control (HbA1c), inflammatory marker (hs-CRP), lipid profile, liver function, and blood pressure were evaluated at baseline, 12, and 24 weeks. Statistical analysis used repeated measures ANOVA and Friedman test (p0.05 significant). Results: Ninety-one participant (57% Female, mean age 45.5 yrs) showed significant improvement (Table). Weight decreased 10.5% and 15.2%; HbA1c reduced 0.96% and 1.78% at 12 and 24 weeks respectively(p0.0001). hs-CRP declined 30-43% (p0.0001). Lipids and BP decreased significantly (p0.0001). Conclusion: The magnitude of cardiometabolic improvement in the Indian population exceeds that reported in Western cohorts, indicating distinct metabolic responsiveness in Indian phenotypes. This study fills a critical evidence gap and supports tirzepatide’s efficacy in South Asians, warranting further research in this underrepresented group. Disclosure A. Jain: None. M. Jain: None. N. Dang: None. A.S. Matharu: None. N.K. Aggarwal: None. S. Ghosh: None. I. Yaduvanshi: None.
JAIN et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: